MedTrace Logo

Maternal Serum Pentraxin 3 in Early Pregnancy to Predict Gestational Diabetes Mellitus

NCT03563638 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 824

Last updated 2018-06-20

No results posted yet for this study

Summary

To investigate the association of maternal serum concentrations of pentraxin 3 in early pregnancy with gestational diabetes mellitus and to explore its potential value in the prediction of GDM.

Conditions

  • Pregnancy Complications Affecting Fetus (Diagnosis)

Interventions

DIAGNOSTIC_TEST

75gOGTT

oral glucose tolerance test (OGTT) was conducted on all participants between the 24th and 28th gestation weeks.The diagnosis of GDM is made when any of the following plasma glucose values are met or exceeded: FPG≥5.1 mmol/L and/or 1h-PG ≥10.0 mmol/L and/or 2h-PG ≥8.5 mmol/ L.

Sponsors & Collaborators

  • Shanghai First Maternity and Infant Hospital

    lead OTHER

Eligibility

Min Age
27 Years
Max Age
33 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-10-01
Primary Completion
2015-12-01
Completion
2015-12-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03563638 on ClinicalTrials.gov